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Abstract
Background: Despite recent advances through the development pipeline, how novel tuberculosis (TB) vaccines
might affect rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR-TB) is unknown. We investigated the
epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic prevention of
disease TB vaccines on RR/MDR-TB in China and India.
Methods: We constructed a deterministic, compartmental, age-, drug-resistance- and treatment history-stratified
dynamic transmission model of tuberculosis. We introduced novel vaccines from 2027, with post- (PSI) or both pre-
and post-infection (P&PI) efficacy, conferring 10 years of protection, with 50% efficacy. We measured vaccine cost-
effectiveness over 2027–2050 as USD/DALY averted-against 1-times GDP/capita, and two healthcare opportunity
cost-based (HCOC), thresholds. We carried out scenario analyses.
Results: By 2050, the P&PI vaccine reduced RR/MDR-TB incidence rate by 71% (UI: 69–72) and 72% (UI: 70–74), and
the PSI vaccine by 31% (UI: 30–32) and 44% (UI: 42–47) in China and India, respectively.
In India, we found both USD 10 P&PI and PSI vaccines cost-effective at the 1-times GDP and upper HCOC thresholds
and P&PI vaccines cost-effective at the lower HCOC threshold. In China, both vaccines were cost-effective at the 1-
times GDP threshold. P&PI vaccine remained cost-effective at the lower HCOC threshold with 49% probability and PSI
vaccines at the upper HCOC threshold with 21% probability. The P&PI vaccine was predicted to avert 0.9 million (UI:
0.8–1.1) and 1.1 million (UI: 0.9–1.4) second-line therapy regimens in China and India between 2027 and 2050,
respectively.
Conclusions: Novel TB vaccination is likely to substantially reduce the future burden of RR/MDR-TB, while averting the
need for second-line therapy. Vaccination may be cost-effective depending on vaccine characteristics and setting.
Keywords: Tuberculosis, Drug resistance, Vaccine, Mathematical model
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: c.weerasuriya@lshtm.ac.uk
†G. B. Gomez and R. G. White contributed equally to this work.
1TB Modelling Group, TB Centre and Centre for the Mathematical Modelling
of Infectious Diseases, Department of Infectious Disease Epidemiology,
Faculty of Epidemiology & Population Health, London School of Hygiene
and Tropical Medicine, London, UK
Full list of author information is available at the end of the article
Weerasuriya et al. BMC Medicine           (2021) 19:60 
https://doi.org/10.1186/s12916-021-01932-7
Background
Rifampicin-resistant and multidrug-resistant tuberculosis
(RR/MDR-TB) threatens to impede global tuberculosis
(TB) control efforts and progress towards the World
Health Organization End TB targets [1], with approxi-
mately half a million incident cases in 2018 [2]. RR/
MDR-TB has worse treatment outcomes than drug-
susceptible TB (DS-TB) and imposes a disproportionate
cost on health systems and patients [3, 4]. Further, pro-
longed multi-agent treatment for RR/MDR-TB may con-
tribute to wider antimicrobial resistance [5]. As such,
there is an urgent need for novel interventions to control
and prevent RR/MDR-TB.
Prophylactic TB vaccine candidates progressed consid-
erably through the development pipeline in 2018–2019.
Results from the M72/AS01E [6] and BCG revaccination
[7] trials suggest possible vaccine efficacy of 50% and
46% in Interferon-γ release assay (IFNy) + and IFNy-
negative patients, respectively. These trials did not in-
clude RR/MDR-TB endpoints due to its relative rarity.
Mathematical modelling techniques could investigate
the potential effect of vaccination on RR/MDR-TB.
However, to date, no modelling studies have assessed
the epidemiologic impact of novel TB vaccines on RR/
MDR-TB. Furthermore, studies of TB vaccine cost-
effectiveness have omitted RR/MDR-TB or not modelled
RR/MDR-TB dynamically [8, 9].
The global distribution of RR/MDR-TB is heterogenous,
with India and China accounting for 27% and 14% of all
global cases, respectively [2]. High-quality national RR/
MDR-TB burden estimates are derived through large and
infrequent drug-resistance surveys; consequently, data to
inform drug resistance trends are sparse. In 2017, globally,
3.5% (95% CI 2.5–4.7%) of new and 18% (95% CI 6.3–
34%) of previously treated TB cases were estimated to
have RR/MDR-TB [10]. Data from China indicate slightly
higher rates, with estimates of 7.1% (95% CI 5.6–8.7) and
24% (95% CI 20–24) RR/MDR-TB among new and previ-
ously treated cases. Data from India indicate slightly
lower-than-global rates. Estimates from the first national
drug-resistance survey, reporting in 2018, place RR/MDR-
TB among new and previously treated cases at 2.8% (CI
2.3–3.5) and 11.6% (10.2–13.2), respectively. Approxi-
mately 69% and 74% of RR-TB cases are estimated to
be MDR-TB (defined as resistance to isoniazid in
addition to rifampicin) in India and China, respectively,
consistent with the global average of 78%. Despite these
similarities, China and India have substantially differing
demographics, TB epidemiology and health systems [2,
11, 12]. As such, in this study, we modelled the epide-
miologic impact, cost-effectiveness and budget impact
of prophylactic vaccination against TB, while dynamic-
ally modelling epidemics of DS- and RR/MDR-TB in
China and India.
Methods
Model structure and calibration
We programmed an age-, treatment history- and drug
resistance-stratified compartmental transmission model
of TB in R [13], extending previously developed methods
[8, 14, 15]. Details of model structure, diagram, equa-
tions, calibration, vaccine implementation, demography
and health economic analysis are described in Add-
itional file 1 [2, 7, 8, 11–14, 16–101]. The model time
horizon was 1950–2050.
The model allowed for five states of TB disease: (1)
susceptible; (2) latently infected; (3) active disease (both
infectious, i.e., bacteriologically sputum-positive, and non-
infectious, i.e., bacteriologically sputum-negative, and
extra-pulmonary); (4) on-treatment; and (5) recovered
from disease, stratified by drug-susceptible/drug-resistant,
and treatment history (Fig. S1 in Additional file 1). All
states were stratified by vaccination status. Transitions
between states represented acquisition of infection, pro-
gression to latency or active disease, conversion of non-
infectious to infectious active disease, detection of active
disease and initiation of treatment, treatment success or
failure, reactivation from latency and relapse from recov-
ered states. Misdiagnosis of RR/MDR-TB was assumed to
lead to inappropriate initiation of DS-TB treatment and
treatment failure. Consistent with empirical data, progres-
sion to active disease following re-infection of latent and
recovered populations was assumed to occur at a lower
rate than naive populations [42]. We assumed that RR/
MDR-TB could develop following drug resistance acquisi-
tion in situ while on treatment for DS-TB or following
transmission of drug-resistant M. tuberculosis. Transmis-
sion could occur between drug-resistance strata. We as-
sumed resistance acquisition and RR/MDR-TB treatment
began in 1970.
Neonates entered the model uninfected. We modelled
0–100 years in 1-year age groups and applied all-cause
mortality to all states, with TB-specific mortality applied
to active-disease and on-treatment states. We applied
age-assortative contact patterns using empirical data for
China [39] and by adapting POLYMOD contact matrices
[40] for India.
We obtained prior ranges for natural history parame-
ters from the literature (Additional file 1, section 2.4),
including age-stratified ranges where available. We as-
sumed RR/MDR-TB was less than or equally transmis-
sible to DS-TB [28, 29]. We constrained rates of fast
progression to active disease, reactivation from latent in-
fection, relapse from recovered state and TB mortality to
be greater or equal in children (age < 15 years) than
adults [21, 47]; in China, we also constrained these rates
to be greater or equal in the elderly (age > 64 years) than
in adults (age 15–64). We applied the opposite con-
straint to natural cure rate [21, 47].
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We used country-specific case-detection rates to inform
diagnosis and treatment initiation [31] (Additional file 1,
section 2.5). RR/MDR-TB was diagnosed through a com-
bined probability of drug-susceptibility testing (deter-
mined by country-specific drug-susceptibility testing
coverage) and empirical diagnosis (Additional file 1, sec-
tion 2.5). We based treatment success for DS-TB and RR/
MDR-TB treatment on historical data [31, 58]. In India,
we adjusted case-detection and DS-TB treatment success
rates for a large private healthcare sector [2, 11, 32], where
we assumed a lower treatment success rate for DS-TB and
unsuccessful treatment of RR/MDR-TB [Rao, R., personal
communication]. Beyond 2018, we maintained constant
rates of treatment initiation, drug-susceptibility testing
coverage and treatment success.
We calibrated the model to historical rates of all TB
prevalence, incidence, notification and mortality [2, 34,
35, 69], RR/MDR-TB incidence rate and percentage RR/
MDR-TB among notifications (stratified by treatment
history) in each country. In India, we fitted to total RR/
MDR-TB treatment initiations in the public sector. In
China, we constrained the number of RR/MDR-TB
treatments contributing to cost-effectiveness calculations
to the number of laboratory-confirmed RR/MDR-TB
treatment initiations reported by China Centres for
Disease Control [31]. Where data allowed, we stratified
calibration targets by age group (< 15, 15–64 and ≥ 65
years in China, and < 15 and ≥ 15 years in India).
Model calibration used Approximate Bayesian Compu-
tation (ABC) rejection-sampling process and ABC Mar-
kov chain Monte Carlo sampling. We randomly
subsampled 1000 fully calibrated parameter sets to gen-
erate model runs, whose median trajectory we used as
an estimate of central tendency and whose maximum
and minimum trajectories represent uncertainty
intervals.
Vaccine implementation
We simulated vaccine introduction in 2027 for each
country and estimated vaccine impact for 2027–2050 by
comparison to the corresponding unvaccinated baseline
model runs.
We modelled two simultaneous vaccination strategies:
routine annual vaccination and mass vaccination cam-
paigns. We assumed routine annual vaccine administration
to 9-year-olds, co-delivered with human papillomavirus
(HPV) vaccine, with coverage of 80%, based on HPV vac-
cine coverage in South Africa and secondary school enrol-
ment ratios in China and India. Mass campaigns were
delivered 10-yearly to ages ≥ 10 at 70% coverage based on
Fig. 1 Model calibration: TB incidence and mortality of RR/MDR-TB and All TB in India and China. Lines represent median model trajectory. RR/
MDR-TB mortality presented for comparison–no calibration targets available. Ribbons represent model uncertainty. Error bars represent calibration
targets and uncertainty. Note: y-axis scales on subplots differ
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existing data for Menafrivac mass campaigns delivered to
1–29-year-olds. We delivered vaccination to populations in
the model who had neither active disease or nor were re-
ceiving treatment, assuming no pre-immunisation testing
for latent TB [73]. No other targeting or eligibility criteria
were applied. We assumed a prevention of disease vaccine,
priced at US$10, conferring 50% efficacy for 10 years, with
vaccine efficacy in individuals with a previous history of M.
tb infection (“post-infection”; PSI) or irrespective of infec-
tion (“pre- and post-infection”; P&PI). Vaccine was mod-
elled as a reduction in the rates of progression to disease
following infection, reactivation from latency and relapse
from the recovered state. The reduction was proportional
to vaccine efficacy. A lower burden of active disease further
depressed the force of infection, leading to lower
rates of M. tb transmission. We modelled vaccination
as equally protective against DS-TB and RR/MDR-TB
and in those with or without previous treatment his-
tory for either. In addition to the direct prevention of
disease mechanism (above), vaccine reduced RR/
MDR-TB burden indirectly by reducing DS-TB bur-
den. Reduced DS-TB burden translated to reduced
total patient-time on treatment for DS-TB, leading to
lower drug-resistance acquisition. Vaccine waning was
implemented as instantaneous at the end of duration
of protection. We did not explicitly represent existing
Bacillus Calmette–Guérin (BCG) immunisation pro-
grammes as we assumed protection conferred by BCG
to be reflected in calibration targets.
As measures of vaccine impact, we calculated percent-
age reduction in incidence rate and mortality rate, in
vaccine scenarios in 2030 and 2050, compared to base-
line and corresponding number of cumulative averted
TB cases and deaths.
Cost, cost-effectiveness and budget impact
We estimated costs from a public sector perspective
using an ingredients approach. Unit cost assumptions,
estimates and full references are provided in Add-
itional file 1, section 5. Briefly, we calculated costs in-
curred by the vaccine and TB programmes.
We estimated three categories of intervention (vaccine
programme) costs: vaccine, delivery and programme
costs. We modelled vaccines priced at US$10 as the base
case. We estimated US$1.13–2.40 (routine) or US$1.20–
2.47 (mass campaign) delivery cost per person vacci-
nated in India, and US$1.60–2.80 for both routine and
mass campaign delivery cost in China. Programme costs
included mass campaign organisation and management,
which we estimated from the literature at US$25,374,949
per campaign in India, and US$16,133.10 per 10,000
persons vaccinated per campaign in China.
TB programme costs represented service costs for TB
diagnosis (including drug-susceptibility testing) and
treatment (Additional file 1, section 5.1). For India, we
added costs representing nutritional support payments
to patients and government incentives to improve TB
case notification in the private healthcare sector. We
inflated historic cost-data to 2018 values where
appropriate.
We calculated incremental costs of vaccination as the
difference in total costs predicted between vaccine and
corresponding baseline scenario.
Using standardised outputs from the model (deaths
due to DS and RR/MDR-TB by age and year and time
spent with active DS and RR/MDR-TB disease), we
calculated total (DS-TB and RR/MDR-TB) disability-
adjusted life years (DALYs) averted by vaccination. We
applied disability weights per the Global Burden of
Disease study [95] and life expectancy from the UN
World Population Prospects [38]. Future costs and
DALYs averted were discounted at 3%.
We calculated incremental cost-effectiveness ratios
(ICERs) for the 1000 vaccine runs and constructed cost-
effectiveness acceptability curves for each vaccine profile
through a probabilistic sensitivity analysis. Input costs
were sampled from their corresponding uncertainty
ranges and attached to each vaccine run. We report the
proportion of ICERs which fall below three illustrative
thresholds per country: 1-times 2018 World Bank gross
domestic product (GDP) per capita and the lowest and
highest healthcare opportunity cost (HCOC) thresholds
estimated by Ochalek et al. [101].
We present budget impact for immunisation and TB pro-
grammes separately. For the immunisation programme, we
present total costs incurred by instantaneous deployment
of vaccine. For the TB programme, we present annual total
costs for programmatic management of TB. Health
economic analysis was undertaken in line with the
Consolidated Health Economic Evaluation Reporting
Standards [102] (Additional file 2).
Scenario analysis
We conducted scenario analyses in two areas: product
related, pertaining to vaccine characteristics and cost,
and baseline related, pertaining to uncertainty in pro-
grammatic (non-vaccine) TB management and associ-
ated future health system investments.
Under product-related scenario analysis, we modelled
vaccines with 30%, 70% and 90% efficacy, 5-years dur-
ation of protection, 30% mass campaign coverage and a
vaccine price of US$30. There are no vaccine candidates
in advanced development that prevent disease solely in
uninfected (i.e., pre-infection) populations. Therefore,
we present vaccines effective pre-infection (PRI) vaccines
as a scenario analysis.
For baseline-related uncertainty, to capture the impact
of vaccination in the context of uncertainty in future
Weerasuriya et al. BMC Medicine           (2021) 19:60 Page 4 of 13
health system investments, and in contrast to the base-
line scenario with no programmatic change after 2018,
we defined an alternative “Policy” scenario, representing
a scaled-up programmatic TB management for each
country (Additional file 1, section 2.6).
For China, the Policy scenario was informed by coun-
try expert opinion. It included linearly scaling up drug-
susceptibility testing coverage to 90% by 2036 and intro-
duction of a standard 9-month RR/MDR-TB treatment
regimen (with the same treatment success rate), linearly
increasing this to 40% of all second-line therapy by 2036
[Li, R., personal communication].
For India, the National Strategic Plan of the Indian Re-
vised National Tuberculosis Control Programme [36] in-
formed the Policy scenario, defined as (1) increased case
detection rate (combined across private and public sec-
tors) to 85%, (2) increased drug-susceptibility testing
coverage among public sector notifications to 100% and
(3) increased proportion of notifications originating from
the private sector to 35%, all by 2025.
Model uncertainty
The final estimates of uncertainty in the results reflect a
combination of epidemiologic input parameter uncer-
tainty (delineated through sampling during calibration)
and cost input uncertainty (incorporated through sam-
pling during the probabilistic sensitivity analysis for
cost-effectiveness analysis).
Role of the funder
The study funder was involved in developing the re-
search question and commented on the draft manu-
script, but had no role in study design, data collection,
analysis, interpretation, nor writing the initial draft. The
corresponding author had full access to all study data
and materials and had final responsibility for the deci-
sion to submit for publication.
Results
Calibration
We calibrated to all TB prevalence, incidence, notifica-
tion and mortality, and to RR/MDR-TB specific rates of
incidence, proportion among all TB notifications (strati-
fied by treatment history) and number of treatment initi-
ations (Fig. 1; further details in Additional file 1, section
6). The model predicted a RR/MDR-TB incidence and
mortality rate per 100,000 in 2018 of 7.8 (UI: 6.7–10.1)
and 2.4 (UI: 1.8–2.8) in India, respectively, and 5.4 (UI:
4.2–5.7) and 0.3 (UI: 0.1–0.4) in China, respectively
(Fig. 1, rows 1 and 3). Baseline epidemiologic projections
(without vaccine) are provided in Additional file 1, sec-
tion 6. The model predicted that RR/MDR-TB incidence
in China was predominantly driven by infection of sus-
ceptible (naive) individuals. In contrast, RR/MDR-TB
incidence in India was driven by equal proportions of
new infection of susceptible and re-infection of latently
infected individuals (Additional file 1, section 7.2).
Epidemiologic impact
A summary of the epidemiologic impact of both P&PI
and PSI vaccines is presented in Figs. 2 and 3 and
Tables 1 and 2.
In India, we found the P&PI vaccine reduced the RR/
MDR-TB incidence rate in 2050 by 72% (UI: 65–77),
corresponding to 2.0 (UI: 1.4–4.1) million cases averted
(Table 1, Fig. 2). The PSI vaccine reduced the RR/MDR-
TB incidence rate in 2050 by 47% (UI: 37–58), corre-
sponding to 1.3 (UI: 0.9–2.6) million cases averted
(Table 1, Fig. 2). The P&PI and PSI vaccines reduced all
TB incidence rate in 2050 by 67% (UI: 59–71) and 44%
(UI: 39–49), respectively (Table 1, Fig. 3).
In China, we found the P&PI vaccine reduced the RR/
MDR-TB incidence rate in 2050 by 73% (UI: 66–76),
corresponding to 2.1 (UI: 1.1–2.7) million cases averted
(Table 2, Fig. 2). The PSI vaccine reduced the RR/MDR-
TB incidence rate in 2050 by 29% (UI: 27–31), corre-
sponding to 0.7 (UI: 0.5–0.9) million cases averted
(Table 2, Fig. 2). The P&PI and PSI vaccines reduced all
TB incidence rate in 2050 by 56% (UI: 53–59) and 37%
(UI: 35–38), respectively (Table 2, Fig. 3).
We found a similar relative effect of P&PI vaccines
compared to PSI vaccines on RR/MDR-TB mortality rate
and deaths averted, and on all TB mortality rate, and
cases and deaths averted (Tables 1 and 2).
Averted treatment
In India, P&PI and PSI vaccines were predicted to avert
0.8 (UI: 0.5–1.4) million and 0.5 (UI: 0.3–1.1) million
RR/MDR-TB treatment regimens (not shown). In China,
the model predicted the P&PI and PSI vaccines would
avert 1.0 (UI: 0.6–1.3) million and 0.3 (UI: 0.2–0.4) mil-
lion RR/MDR-TB treatment regimens, respectively (not
shown).
Cost-effectiveness
In India, in a discounted analysis, we estimated ICERs of
$151 (UI: 82–210) and $284 (UI: 189–389) for P&PI and
PSI vaccines priced at USD 10, respectively (Fig. 4), over
2027–2050. The P&PI vaccine was predicted to be cost-
effective in 100% of model runs at the 1-times GDP, and
upper and lower HCOC thresholds. The PSI vaccine was
predicted to be cost-effective in 100%, 99% and 27% of
runs at the 1-times GDP, upper HCOC and lower
HCOC thresholds, respectively.
In China, in a discounted analysis, we estimated ICERs
of $3663 (UI: 2763–4754) and $6059 (UI: 4591–7749)
for P&PI and PSI vaccines priced at USD 10, respectively
(Fig. 4), over 2027–2050. The P&PI vaccine was
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predicted to be cost-effective in 100% of runs at the 1-
times GDP threshold and upper HCOC threshold, and
49% of runs at the lower HCOC threshold. The PSI vac-
cine was cost-effective at 100% and 21% of runs at the 1-
times GDP and upper HCOC threshold, but not cost-
effective at the lower HCOC threshold.
Budget impact
The total undiscounted costs for instantly deployed
mass campaigns and routine annual vaccination for a
50% efficacy P&PI vaccine providing 10 years of pro-
tection and total savings in the TB programme over
2027–2050 are presented in Table 3. Immunisation
programme costs were similar for a PSI vaccine
priced at US$10 in India and China (Additional file 1,
section 9) but with lower TB programme savings. The
total annual expenditure by the National Tuberculosis
Programmes for India and China over 2027–2050 is
shown in Fig. 5.
Scenario analyses
We found increasing vaccine efficacy increased percent in-
cidence rate reduction, cases averted, percent mortality
rate reduction, deaths averted in both RR/MDR-TB and
all TB, and averted DS-TB and RR/MRD-TB treatment
regimens. Reduced duration of protection to 5 years or re-
duced vaccine efficacy (Additional file 1, sections 7.3 and
7.4) had the opposite effect. PRI vaccines had a compar-
able or lower impact than PSI vaccines in all cases except
for RR/MDR-TB in China, where PRI effect was greater
than PSI (Additional file 1, sections 7.2 and 7.3).
We found vaccines (of all types, efficacies and
durations of protection) affected a similar per cent
incidence rate reduction and per cent mortality rate
reduction in both all TB and RR/MDR-TB, in both India
and China, in the Policy scenario as compared to the
unchanged baseline. Fewer cases and deaths were averted
in the Policy scenario, leading to a lower absolute
impact of vaccination. ICERs for vaccination were
higher in undiscounted analyses, with a vaccine priced
at US$30, and in the Policy scenario for each country
(Additional file 1, section 8).
Discussion
We estimate that the introduction of new TB vaccines in
India and China in 2027 might substantially reduce RR/
MDR-TB burden by 2050. A pre- and post-infection
vaccine (effective in all individuals, irrespective of their
infection status by M. tb) was projected to reduce RR/
MDR-TB incidence rate by approximately 70% in both
India and China if delivered annually to 9-year-olds and
every 10 years to ages 10 and above. A post-infection
vaccine (effective only in individuals with latent M. tb
infection or who have recovered from TB) was projected
Fig. 2 Incidence rate reduction of all TB by 50% efficacy, 10-year duration of protection pre- and post-infection efficacy (P&PI) and post-infection
efficacy (PSI) vaccines in India (top) and China (bottom). Lines represent median model incidence rate; ribbons represent model uncertainty.
Vaccine is introduced in 2027. Note: y-axis scales on subplots differ
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to impart lower but still substantial reductions of ap-
proximately 50% and 30% RR/MDR-TB incidence rate
reduction in India and China, respectively.
P&PI vaccines priced at US$10 were highly likely to
be cost-effective in India and China at the 1-times
GDP and upper HCOC thresholds. In India, P&PI
vaccines were also likely to be cost-effective at the
lower HCOC threshold. While we found PSI vaccines
to be less cost-effective than P&PI vaccines in gen-
eral, a PSI vaccine priced at US$10 remained highly
likely to be cost-effective at the 1-times GDP
threshold in both India and China and at the upper
HCOC threshold in India. In both countries, vaccin-
ation was projected to avert approximately 1 million
RR/MDR-TB regimens by 2050.
We attributed the greater PSI vaccine impact on RR/
MDR-TB in India than China, to the proportionally
greater rate of re-infection and fast progression of latent
RR/MDR-TB (which is avertible through post-infection
vaccine efficacy) at baseline (Additional file 1, section
7.2). Moreover, in China, the RR/MDR-TB epidemic—
driven by new infections among susceptible (naive)
Fig. 3 Incidence rate reduction of RR/MDR-TB by 50% efficacy, 10-year duration of protection pre- and post-infection efficacy (P&PI) and post-
infection efficacy (PSI) vaccines in India (top) and China (bottom). Lines represent median model incidence rate; ribbons represent model
uncertainty. Vaccine is introduced in 2027
Table 1 India–Epidemiologic impact for 50% efficacy, 10-year duration of protection vaccines. Estimates are median (uncertainty
interval) values. Incidence and mortality rate reductions compare annual values of vaccine vs baseline in 2030 and 2050. Cases and
deaths averted are cumulative over 2027–2030 and 2027–2050
Pre- and post-infection vaccine Post-infection vaccine
Resistance status Outcome 2030 2050 2030 2050
RR/MDR-TB % Incidence rate reduction in year 42% (37–45) 72% (65–77) 27% (20–34) 47% (37–58)
% Mortality rate reduction in year 20% (15–24) 69% (60–75) 13% (8–19) 45% (33–55)
Cumulative cases averted, millions 0.2 (0.1–0.3) 2.0 (1.4–4.1) 0.1 (0.1–0.2) 1.3 (0.9–2.6)
Cumulative deaths averted, millions 0.015 (0.008–0.02) 0.4 (0.3–0.7) 0.009 (0.004–0.015) 0.3 (0.2–0.4)
All TB % Incidence rate reduction in year 47% (41–51) 67% (59–71) 34% (28–39) 44% (39–49)
% Mortality rate reduction in year 36% (28–41) 66% (59–71) 25% (18–31) 44% (38–49)
Cumulative cases averted, millions 6.1 (5.0–7.0) 57.1 (45.9–70.0) 4.3 (3.3–5.2) 39.6 (31.4–48.2)
Cumulative deaths averted, millions 0.4 (0.3–0.5) 5.9 (4.7–7.9) 0.3 (0.2–0.3) 4.1 (3.0–5.3)
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individuals—was more impacted by PRI than PSI vaccine
efficacy (Additional file 1, section 7.2).
We found that vaccination averted a substantially higher
absolute number of all TB cases and deaths in India than
China. This reflected higher TB incidence and substan-
tially higher TB mortality at baseline in India than China.
The greater averted burden translated to greater averted
life-years otherwise lost to TB; thus, despite lower TB
management costs, for all vaccine profiles, ICERs in India
were lower than in China. Correspondingly, savings in the
TB programme were greater in India than China and re-
flect an underestimate for both countries, as vaccine-
mediated protection and the dynamic impact of vaccin-
ation on the TB epidemic would continue to suppress TB
burden beyond the model time horizon.
This study had several limitations pertaining to (1)
model parameterisation and structure, (2) baseline sce-
narios and (3) vaccine implementation, which we con-
sider in turn.
Data to substantiate natural history parameters for
RR/MDR-TB were sparse and heterogeneous [28, 103,
104]. We assumed RR/MDR-TB transmissibility was
equal to or lower than DS-TB [28, 29] and sampled from
wide parameter priors. In the absence of evidence or a
priori reasoning for differing values, we assumed other
RR/MDR-TB and DS-TB parameters had the same
values. As new empirical evidence arises, our predictions
and estimates can be updated, but it is currently difficult
to identify their direction of bias. Further, we maintained
constant country-specific contact patterns over the
model time horizon between DS and RR/MDR-TB. If in-
dividuals with RR/MDR-TB were to mix with one an-
other preferentially, our results may overestimate
vaccine impact.
To test our baseline assumptions of post-2018 constant
case detection rates and drug-sensitivity testing coverage,
we implemented a contrasting scaled up programmatic
management scenario based on country-specific national
policy. Our conclusions regarding relative vaccine impact
remained robust to programmatic scale-up. However, we
did not change RR/MDR-TB treatment success rate nor
introduce a theoretical future highly effective diagnostic
Table 2 China–Epidemiologic impact for 50% efficacy, 10-year duration of protection vaccines. Estimates are median (uncertainty
interval) values. Incidence and mortality rate reductions compare annual values of vaccine vs baseline in 2030 and 2050. Cases and
deaths averted are cumulative over 2027–2030 and 2027–2050
Pre- and post-infection vaccine Post-infection vaccine
Resistance status Outcome 2030 2050 2030 2050
RR/MDR-TB % Incidence rate reduction in year 44% (42–46) 73% (66–76) 14% (13–16) 29% (27–31)
% Mortality rate reduction in year 22% (18–24) 67% (59–72) 8% (6–10) 28% (25–30)
Cumulative cases averted, millions 0.2 (0.1–0.2) 2.1 (1.1–2.7) 0.05 (0.04–0.06) 0.7 (0.5–0.9)
Cumulative deaths averted, millions 0.003 (0.001–0.005) 0.1 (0.0–0.2) 0.001 (0.001–0.002) 0.04 (0.02–0.06)
All TB % Incidence rate reduction in year 42% (40–44) 56% (53–59) 28% (26–29) 37% (35–38)
% Mortality rate reduction in year 29% (26–32) 53% (48–58) 21% (18–24) 35% (33–36)
Cumulative cases averted, millions 1.4 (1.2–1.5) 10.5 (8.9–12.0) 0.9 (0.8–1.0) 6.9 (5.9–7.8)
Cumulative deaths averted, millions 0.02 (0.01–0.04) 0.4 (0.2–0.5) 0.02 (0.01–0.03) 0.3 (0.1–0.4)
Fig. 4 Cost-effectiveness acceptability curves. Vertical axis shows the probability that 50% efficacy, 10-year duration of protection pre-and post-
infection (P&PI; top) and post-infection (PSI; bottom) vaccines are cost-effective at or below a given willingness to pay value (horizontal axis), in
India (left) and China (right). Reference lines are 2018 World Bank GDP and upper and lower health-care opportunity-cost thresholds. Note: x-axis
scales differ between subplots
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technology, either of which may reduce vaccine impact es-
timates. In India, we assumed the private health sector did
not treat RR/MDR-TB successfully, based on in-country
expert opinion. Should overall treatment success improve
because of a larger private sector engagement effort, rela-
tive vaccine impact might remain stable, but absolute im-
pacts may be reduced. We cannot speculate on the impact
on cost-effectiveness, as this would depend on the specific
mechanism of increased private sector engagement.
Should the strategic focus of the Indian National Tubercu-
losis Programme change to include improved RR/MDR-
TB treatment in the private healthcare sector, a new
baseline scenario could be modelled to estimate the po-
tential effect on vaccine impact. In China, we assumed the
number of RR/MDR-TB treatment initiations contributing
to programme costs was equal to the number starting
treatment as reported by the Chinese Centre for Disease
Control and Prevention (CDC). However, the averted
number of treatments estimate applies to all RR/MDR-TB
treatment—both CDC and non-CDC. As the total RR/
MDR-TB treatment volume is unconstrained, our result
of averted treatment may be an overestimate. We confined
our health-economic analysis to a public sector healthcare
perspective. TB-related costs to patients, including indir-
ect costs from seeking healthcare and productivity losses,
can be substantial [3]; these costs are not factored into our
cost-effectiveness analysis. However, our analysis does in-
clude TB programme costs related to patient and private
sector support: in India, we included nutritional support
payments to TB patients and payments to incentivise pri-
vate sector healthcare providers.
We implemented vaccine waning as an instantaneous
loss of efficacy. If empirical data suggested a different
waning shape, our estimates may over or underestimate
the impact. We did not investigate vaccine targeting (e.g.
by age, or by RR/MDR-TB risk group); targeting could
improve cost-effectiveness estimates but reduce overall
impact. We assumed population-wide mass campaigns
were deployed instantaneously, with simultaneously ap-
plied costs, instead of through phased multi-year
Fig. 5 Budget impact analysis. Annual expenditure by the national TB programmes TB-related costs. Vertical axis represents annual expenditure, in
millions USD, by the national TB programme, with and without vaccine, in India (top) and China (bottom). Lines represent median modelled
expenditure; ribbons represent model uncertainty
Table 3 Estimated cumulative total cost of vaccine
programmes and cumulative TB programme savings over 2027–
2050. Costs are presented for a 50% efficacy P&PI vaccine
providing 10-years of protection. All costs are undiscounted and
in billions USD
Type Amount
India Routine vaccination costs $5.2 (4.9–5.4)
Mass vaccination costs $33.4 (31.9–34.6)
All vaccination programme costs $38.6 (37.1–39.9)
TB Programme savings $19.4 (13.0–27.2)
China Routine vaccination costs $3.4 (3.2–3.5)
Mass vaccination costs $38.1 (36.4–39.2)
All vaccination programme costs $41.5 (39.8–42.6)
TB programme savings $5.2 (3.9–6.8)
Weerasuriya et al. BMC Medicine           (2021) 19:60 Page 9 of 13
campaigns. These assumptions have one main conse-
quence: vaccine-associated costs, which were calculated
assuming that countries do not need additional capacity
to deliver these campaigns, are an underestimate. How-
ever, as the benefits of such campaigns were also realised
from the start, the ICERs may not be an underestimate.
Finally, while we capture the cost-savings due to averted
RR/MDR-TB treatment, the positive externalities this af-
fords through a reduced contribution to antimicrobial
resistance are not included in the cost-effectiveness ana-
lysis. We assumed a US$10 price per vaccine course and
vaccine introduction in 2027. Should vaccine price de-
cline over time, this might increase the probability of
cost-effectiveness at the low HCOC threshold in either
country or of PSI vaccines in China at the upper HCOC
threshold. We speculate that delayed vaccine introduc-
tion by a few years would affect vaccine costs and bene-
fits to similar extents and so is unlikely to substantially
alter our findings.
Any evaluation of new TB vaccines must be compared
to BCG. Neonatal BCG is still offered routinely in India
and China [105]. Epidemiologic evidence suggests that
BCG prevents severe disease—particularly miliary tuber-
culosis and tuberculous meningitis—in young children
[106]. The effect of neonatal BCG vaccination on pul-
monary tuberculosis risk in adults with estimates ran-
ging from none to substantial [107–109]. Current
evidence indicates that neonatal BCG vaccination will be
inadequate to end transmission of M. tb among adults,
which is a prerequisite for global TB elimination. In con-
trast, we suggest that adolescent and adult vaccination—
with efficacy similar to late-stage vaccine candidate
M72/AS01E—which prevents pulmonary TB disease may
be a useful contributor towards this goal.
Previous estimates of TB vaccine cost-effectiveness ei-
ther omit MDR-TB or do not model MDR-TB dynamic-
ally [8, 9]. This is the first study to dynamically model
the impact of potential novel vaccines on MDR-TB. We
modelled both the de novo acquisition of drug-
resistance and transmission of drug-resistant M. tuber-
culosis. We also developed a country-specific cost model
and estimated the cost-effectiveness of these vaccines.
Consequently, our ICER estimates incorporated both the
direct impact of vaccination on RR/MDR-TB and indir-
ect effects due to reduced transmission. In India, we also
adjusted for differential treatment by the private sector.
Conclusions
Novel TB vaccination is likely to substantially reduce the
future burden of RR/MDR-TB, while averting the need
for RR/MDR-TB treatment. Vaccination may be cost-
effective, but this depends on the local context and spe-
cific characteristics of the vaccine. There is an urgent
need for new TB vaccines to prevent disease and for
further investment in and acceleration of development
of such vaccines to progress towards global TB elimin-
ation goals. As development of such vaccines continues,
decision-makers should consider their potential role in
national tuberculosis programmes and in wider anti-
microbial resistance control efforts.
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